MwanzoATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
Bei iliyotangulia
$ 0.22
Bei za mwaka
$ 0.11 - $ 0.89
Wastani wa hisa zilizouzwa
elfu 27.54
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CAD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 4.60M | -1.42% |
Mapato halisi | -4.21M | 2.39% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.08 | -32.96% |
EBITDA | — | — |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CAD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 24.91M | -41.20% |
Jumla ya mali | 56.36M | -23.56% |
Jumla ya dhima | 30.42M | -0.13% |
Jumla ya hisa | 25.94M | — |
hisa zilizosalia | 52.67M | — |
Uwiano wa bei na thamani | 0.44 | — |
Faida inayotokana na mali | -19.71% | — |
Faida inayotokana mtaji | -41.30% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CAD) | Des 2023info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -4.21M | 2.39% |
Pesa kutokana na shughuli | -3.84M | -6.66% |
Pesa kutokana na uwekezaji | 11.04M | 1,975.38% |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | 7.20M | 334.09% |
Mtiririko huru wa pesa | -2.47M | -2,419.13% |
Kuhusu
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Ilianzishwa
2009
Tovuti
Wafanyakazi
11
